54 6.7 References

Albuminuria. (2015, December 24). Retrieved December 5, 2019, from National Kidney Foundation website: https://www.kidney.org/atoz/content/albuminuria

Amlodipine and Atorvastatin For High Cholesterol and Blood Pressure—Overview. (2015). Retrieved from https://www.youtube.com/watch?v=zOts-t6Ys9A

Atherosclerosis | Men’s Health Resource Center. (n.d.). Retrieved December 4, 2019, from http://www.menshealthresourcecenter.com/conditions/atherosclerosis/.

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., … Collins, R. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. The Lancet, 377(9784), 2181–2192. https://doi.org/10.1016/S0140-6736(11)60739-3

Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic Kidney Disease Diagnosis and Management: A Review. JAMA, 322(13), 1294–1304. https://doi.org/10.1001/jama.2019.14745

Cho, E.Y., et al. Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease. (2017). PLOS ONE,  12(1), p. e0170017. https://doi:10.1371/journal.pone.0170017.

Cholesterol levels by age: Differences and recommendations. (n.d.). Retrieved December 5, 2019, from Medical News Today website: https://www.medicalnewstoday.com/articles/315900.php

Chronic Kidney Disease: Are You At Risk? (2017). Retrieved December 3, 2019, from Villa Medica website: https://villa-medica.com/cell-therapy-for-ckd/

Chronic Kidney Disease – Causes, Symptoms, Diagnosis, Treatment, Pathology – YouTube. https://www.youtube.com/watch?v=fv53QZRk4hs. Accessed 7 Dec. 2019.

Conard, S. E., Bays, H. E., Leiter, L. A., Bird, S. R., Rubino, J., Lowe, R. S., … Tershakovec, A. M. (2008). Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. The American Journal of Cardiology, 102(11), 1489–1494. https://doi.org/10.1016/j.amjcard.2008.09.075

Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., & Prat, A. (2004). Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(8), 1454–1459. https://doi.org/10.1161/01.ATV.0000134621.14315.43

Farhadnejad, H., Asghari, G., Emamat, H., Mirmiran, P., & Azizi, F. (2019). Low-Carbohydrate High-Protein Diet is Associated With Increased Risk of Incident Chronic Kidney Diseases Among Tehranian Adults. Journal of Renal Nutrition, 29(4), 343–349. https://doi.org/10.1053/j.jrn.2018.10.007

Fralick, M., Avorn, J., Franklin, J. M., Bartsch, E., Abdurrob, A., & Kesselheim, A. S. (2018). Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. Journal of General Internal Medicine, 33(6), 792–794. https://doi.org/10.1007/s11606-018-4349-2

Fraser, S. D., & Blakeman, T. (2016). Chronic kidney disease: Identification and management in primary care. Pragmatic and Observational Research, 7, 21–32. https://doi.org/10.2147/POR.S97310

Husain, N. E., Hassan, A. T., Elmadhoun, W. M., & Ahmed, M. H. (2015). Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): What are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? Expert Opinion on Drug Safety, 14(9), 1445–1455. https://doi.org/10.1517/14740338.2015.1063613

Juraschek, S. P., Chang, A. R., Appel, L. J., Anderson, C. A. M., Crews, D. C., Thomas, L., … Miller, E. R. (2016). Effect of glycemic index and carbohydrate intake on kidney function in healthy adults. BMC Nephrology, 17(1), 70. https://doi.org/10.1186/s12882-016-0288-5

Kimura, Genjiro, et al. (2017). “Effects of Atorvastatin on Renal Function in Patients with Dyslipidemia and Chronic Kidney Disease: Assessment of Clinical Usefulness in CKD Patients with Atorvastatin (ASUCA) Trial.” Clinical and Experimental Nephrology, 21(3), 417–424., doi:10.1007/s10157-016-1304-6.

Konrad, R. J., Troutt, J. S., & Cao, G. (2011). Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids in Health and Disease, 10, 38. https://doi.org/10.1186/1476-511X-10-38

Laursen, D. R. T., Paludan-Müller, A. S., & Hróbjartsson, A. (2019). Randomized clinical trials with run-in periods: Frequency, characteristics and reporting. Clinical Epidemiology, 11, 169–184. https://doi.org/10.2147/CLEP.S188752.

Leiter, L. A., Bays, H., Conard, S., Bird, S., Rubino, J., Hanson, M. E., … Tershakovec, A. M. (2008). Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. The American Journal of Cardiology, 102(11), 1495–1501. https://doi.org/10.1016/j.amjcard.2008.09.076

Levin, A. (2003). Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Seminars in Dialysis, 16(2), 101–105. https://doi.org/10.1046/j.1525-139x.2003.16025.x

Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia. (n.d.). Retrieved December 7, 2019, from Clinical Trials Arena website: https://www.clinicaltrialsarena.com/projects/liptruzet-ezetimibe-and-atorvastatin-for-the-treatment-of-hyperlipidaemia/

Liver Disease Symptoms, Signs, Diet & Treatment. (n.d.). Retrieved December 7, 2019, from https://www.medicinenet.com/liver_disease/article.htm

McKenney, J. M., Jones, P. H., Bays, H. E., Knopp, R. H., Kashyap, M. L., Ruoff, G. E., & McGovern, M. E. (2007). Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis, 192(2), 432–437. https://doi.org/10.1016/j.atherosclerosis.2006.11.037

Nutescu, E. A., & Shapiro, N. L. (2003). Ezetimibe: A selective cholesterol absorption inhibitor. Pharmacotherapy, 23(11), 1463–1474. https://doi.org/10.1592/phco.23.14.1463.31942

Pablos-Méndez, A., Barr, R. G., & Shea, S. (1998). Run-in periods in randomized trials: Implications for the application of results in clinical practice. JAMA, 279(3), 222–225. https://doi.org/10.1001/jama.279.3.222

Phan, B. A. P., Dayspring, T. D., & Toth, P. P. (2012). Ezetimibe therapy: Mechanism of action and clinical update. Vascular Health and Risk Management, 8, 415–427. https://doi.org/10.2147/VHRM.S33664

Pickering, J. W., Frampton, C. M., Walker, R. J., Shaw, G. M., & Endre, Z. H. (2012). Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Critical Care, 16(3), R107. https://doi.org/10.1186/cc11391

Razmaria, A. A. (2016). Chronic Kidney Disease. JAMA, 315(20), 2248–2248. https://doi.org/10.1001/jama.2016.1426

Rosenthal, R. L. (2000). Effectiveness of altering serum cholesterol levels without drugs. Proceedings (Baylor University. Medical Center), 13(4), 351–355.

Simonyi, G., & Tamás, F. (2016). One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy. Atherosclerosis, 252, e56. https://doi.org/10.1016/j.atherosclerosis.2016.07.415

The new state of statins. Retrieved December 4, 2019, from Harvard Health website: https://www.health.harvard.edu/drugs-and-medications/the-new-state-of-statins

Triglyceride Levels: High, Low & Normal Ranges. (n.d.). Retrieved December 5, 2019, from MedicineNet website: https://www.medicinenet.com/triglyceride_test/article.htm

Zodda, D., Giammona, R., & Schifilliti, S. (2018). Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy (Basel, Switzerland), 6(1). https://doi.org/10.3390/pharmacy6010010